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Background: Insomnia is a widespread human health problem, but there currently are the limitations of
conventional therapies available. Suanzaoren decoction (SZRD) is a well known classic Chinese herbal prescription
for insomnia and has been treating people’s insomnia for more than thousand years. The objective of this study
was to evaluate the efficacy and safety of SZRD for insomnia.
Methods: A systematic literature search was performed for 6 databases up to July of 2012 to identify randomized
control trials (RCTs) involving SZRD for insomniac patients. The methodological quality of RCTs was assessed
independently using the Cochrane Handbook for Systematic Reviews of Interventions.
Results: Twelve RCTs with total of 1376 adult participants were identified. The methodological quality of all
included trials are no more than 3/8 score. Majority of the RCTs concluded that SZRD was more significantly
effective than benzodiazepines for treating insomnia. Despite these positive outcomes, there were many
methodological shortcomings in the studies reviewed, including insufficient information about randomization
generation and absence of allocation concealment, lack of blinding and no placebo control, absence of
intention-to-treat analysis and lack of follow-ups, selective publishing and reporting, and small number of sample
sizes. A number of clinical heterogeneity such as diagnosis, intervention, control, and outcome measures were also
reviewed. Only 3 trials reported adverse events, whereas the other 9 trials did not provide the safety information.
Conclusions: Despite the apparent reported positive findings, there is insufficient evidence to support efficacy of
SZRD for insomnia due to the poor methodological quality and the small number of trials of the included studies.
SZRD seems generally safe, but is insufficient evidence to make conclusions on the safety because fewer studies
reported the adverse events. Further large sample-size and well-designed RCTs are needed.
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Description of the condition
Insomnia is a highly prevalent, often debilitating, and eco-
nomically burdensome sleep disorder, associating with vari-
ous situational, medical, emotional, environmental and
behavioral factors [1]. It is estimated that 25% to 30% of
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reproduction in any medium, provided the orencounter chronic insomnia that meet diagnostic criteria
for insomnia with the presence of symptoms for at least
1 month [2,3]. Health troubles associated with insomnia in-
clude lower quality of life, greater use of medical services as
well as decreased work efficiency [4]. Insomnia is also asso-
ciated with higher risk of depression and augment rates of
absenteeism [5,6].
Currently, a proportion of insomniac patients worldwide
resort to various kinds of complementary and alternative
medicine (CAM). An analysis of the United States National
Health Interview Survey data from 2002 by Pearson et al.
[7] revealed that 4.5% of adult population had used CAM to. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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12 months. A population-based pharmacoepidemiology sur-
vey of Chinese herbs for treating insomnia in Taiwan during
2002 indicated that the peak age of these subjects with in-
somnia treated by traditional Chinese medicine (TCM) was
between 40 and 49 years (25.3%), followed by 30-39 years
(23.8%) and 50-59 years (17.0%) [8].
Description of the intervention
In western conventional medicine (WCM), guidelines of
British association for psychopharmacology (BAP) recom-
mend that cognitive behavioral therapy (CBT) is an effect-
ive treatment for insomnia delivered either individually or
in small group format (Ia), and has been found to be as ef-
fective as prescription medications for short-term treat-
ment of chronic insomnia (Ia) [9]. However, there is still
limited evidence of clinically meaningful changes beyond
reductions of insomnia symptoms such as improved day-
time functioning, quality of life [10]. In addition, it remains
largely underutilized because there are few trained thera-
pists [9] and patient adherence is an issue [11]. Guidelines
of BAP recommended that Z-drugs and short-acting ben-
zodiazepines are efficacious for insomnia (Ia), and pro-
longed release melatonin improves sleep onset latency and
quality in patients over 55 (Ib) [9]. However, benzodiazep-
ine receptor agonists is limited by concerns regarding
long-term efficacy and the potential for abuse, depend-
ence, and adverse effects [12]. Clinical application of pro-
longed release melatonin was only recommended
treatment of insomnia in the elderly for 3 weeks (1b) [9],
and no consistent conclusion could be drawn so far [13].
TCM including Chinese herbal medicine (CHM), acu-
puncture and other nonmedication therapies has played
an important role in the medical care of insomnia patients
for more than 2000 years [14]. In a typical CHM prescrip-
tion, a complex integration of two or more single Chinese
herbs together formed a formula to achieve additive or
synergistic effects. Based on the Chinese diagnostic pat-
terns, i.e., inspection, listening, smelling, inquiry, and pal-
pation, the CHM prescription follows a completely
different rationale than many western drug treatments
[15]. Suanzaoren Decoction (SZRD) is composed of 5
kinds of CHMs: Suanzaoren, Fuling (Poria, Hoelen),
Chuanxiong (Rhizoma Chuanxiong, Ligusticum), Zhimu
(Rhizoma Anemarrhenae, Anemarrhena), and Gancao
(Radix Glycyrrhizae, Licorice) [16], all of which are
recorded in the Chinese Pharmacopoeia (Version 2010).
SZRD is one of most famous herbal prescriptions for in-
somnia, which firstly documented in the classical Chinese
medical book JinGuiYaoLue (Synopsis of Prescriptions of
the Golden Chamber) by Zhang Zhongjing (AD 152-219)
at the end of the Han Dynasty [16]. In modern time, SZRD
are still widely used throughout China and elsewhere in the
world for the treatment of insomnia. A survey researchfrom Taiwan [8] and a recently published systematic review
[14] showed that SZRD was one of the most commonly
prescribed Chinese herbal prescription for insomnia.How the intervention might work
In experimental studies, SZRD showed the hypnotic effect
on sleep enhancement and its underlying mechanisms may
be mediated through the activation of serotonergic system
in additional to the activation of Gamma-aminobutyric acid
A (GABAA) receptors in rat [17,18]. At the global metabo-
lomics levels, SZRD can increase sleep activity and exhibit
binding affinity for serotonin receptors in a model of in-
somnia drosophila [19]. Semen ziziphi spinosae, as the prin-
cipal drug in the SZRD, has exhibited the central nervous
system tranqualizing effect. Spinosin has been proposed as
the active component in Semen ziziphi spinosae [20]. It has
been reported jujubogenin through the hydrolysis of the
saponin jujuboside A to be the effective suanzaoren con-
stituent to interact directly with the GABAA receptor [21].
In addition, the hypnotic effect of zizyphi spinosi semen
may be mediated by the anticholinergic and antihistamine
action of betulic acid, an active compound of zizyphi spi-
nosi semen [22,23].Why it is important to do this review
Currently, prescriptions of CHMs for insomnia largely
reflect the experience of the Chinese herbal doctor or
what is recommended by traditional Chinese texts [8].
In the classical literature, SZRD is proposed to nourish
the blood and calm the nerves to eventually bring on a
tranquillizing sensation and reduce the effect of sleep
disturbance [16]. Evidence-based medicine (EBM) is a
strategy for the critical evaluation and uniform compari-
son of clinical trial data with conclusions according to
predetermined efficacy criteria. Owing to the significant
health risk of insomnia and the limitations of currently
available conventional therapies, there have been a num-
ber of controlled studies over the past decade to evaluate
the efficacy and safety of SZRD for insomnia. A system-
atic review addressing the efficacy of modified SZRD for
insomnia has also been published recently with 13 RCTs
in Chinese, and it concluded that the total effective rate
in modified SZRD group was better than that in control
group [24]. However, this low-quality systematic review
had many shortcomings as follows and language barriers
which is not readily accessible to Western scientists. For
example, the authors only searched three Chinese data-
bases from 2000 to 2010; evaluation of SZRD by com-
paring another form of CHMs in control group also was
included; 6 of 13 studies were co-morbid insomnia as
secondary to another condition; the conclusions are not
scientifically sound and very misleading. Therefore, it is
worthwhile to undertake a update systematic review of
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Objective
Given the gap between the lack of scientific evidence for
the efficacy of SZRD and the widespread use and grow-
ing enthusiasm among the public possibly due to the
limitations of conventional therapies available, the ob-
jective of current systematic review is an updated and
English version to evaluate the efficacy and safety of
SZRD for primary insomnia.
Methods
This systematic review is conducted according to the
Preferred Reporting Items for Systematic Reviews and




Only randomized controlled trials (RCTs) which evaluate
SZRD for primary insomnia were included in this review,
regardless of blinding, publication status or language.
Quasi-RCTs, for example, allocation by date of birth, day
of the week, medical record number, month of the year, or
the order in which participants are included in the study
(alternation) were excluded.
Types of participants
Participants diagnosed with primary insomnia according to
Chinese classification of mental disorders (CCMD)-2-R and
the update version CCMD-3 [26] or Guideline for Clinical-
Trials of New Patent Chinese Medicines (GCTNPCM)
criteria [27] were included, regardless of age, gender and
ethnicity. The CCMD-3 criteria is as follows: (1) one or
more of the following sleep related complaints: difficulty
initiating sleep, sleep not deep, waking up too early, too
much dream, not easy to sleep again after waking up, un-
comfortable after waking up, fatigue and daytime sleepi-
ness; (2) the symptom of insomnia that has been present
for three or more times a week and persist for at least a
month; (3) marked distress due to discontent about the
quantity and quality of sleep, or vocational dysfunction;
(4) to exclude secondary insomnia caused by or co-
morbid with physical illness and mental disorders etc. The
GCTNPCM criteria is as follows: (1) Patients with the typ-
ical symptoms of insomnia: difficulty initiating sleep, often
nocturnal awakenings, difficulty maintaining sleep or not
easy to sleep again after waking up, wake up early in the
morning, difficulty initiating sleep, the nighttime sleep dif-
ficulty, daytime sleepiness, sleep less than 5 hours; (2) a
history of recurrent insomnia and persist for at least a
month; (3) the degree classification of insomnia. Mild:
often nocturnal awakenings or difficulty maintaining sleep,wake up early in the morning, but do not affect vocational
dysfunction; Moderate: Sleep less than 4 hours, but can
adhere to the work; Severe: Up all night, difficult to persist
in the normal work; (4) to exclude secondary insomnia
caused by or co-morbid with physical illness and mental
disorders etc.; (5) adults 18-65 years of age.
Types of intervention
Studies which used SZRD as a monotherapy or as an ad-
junct therapy to conventional medicine were included.
There is no restriction on dosage including frequency,
dose, and intensity. The duration of treatment courses was
at least 2 weeks. Comparator interventions were conven-
tional medicine (Benzodiazepine), placebo, or no treat-
ment. Studies comparing SZRD with another CHM were
excluded. The definition of modified SZRD is at least 4
out of 5 herbs in SZRD or plus a few herbs based on dif-
ferentiation of syndrome, but the prescription must in-
clude the principal drug, Semen ziziphi spinosae.
Types of outcome measures
The primary outcome measurement was sleep question-
naires such as the Pittsburgh Sleep Quality Index (PSQI)
[28], the Spiegel sleep questionnaire [29], sleep dysfunc-
tion rating scale [30] at the end of the treatment course.
The secondary outcome measurement was the clinical
effective rate based on response evaluation criteria in
TCM treatment of insomnia [27], and the adverse
events. In Guideline for Clinical Trials of New Patent
Chinese Medicines, evaluation standards for clinical
therapeutic effects were as follows [27]: (1) clinical cure:
sleep time to restore normal sleep time or the nighttime
sleep duration of more than 6 hours, deep sleep, full of
energy after waking up; (2) markedly effective: significant
improvement of insomnia; sleep time increased over
3 hours compared with the previous sleep time; an in-
crease of the depth of sleep; (3) effective: amelioration in
symptoms; sleep time increased less than 3 hours com-
pared with the previous sleep time; (4) ineffective: no
significant improvement of insomnia, or deteriorated
after treatment. Other assessment criteria of clinical
therapeutic effect made by other authors with compar-
able definitions were also considered. However, we
excluded the trials due to deficiency of useful data.
Literature search
We electronically searched Cochrane Central Register
of Controlled Trials (CENTRAL), PubMed, EMBASE,
Chinese National Knowledge Infrastructure (CNKI), VIP
information database, and Wanfang Data Information
Site. The publication time is from the start of each data-
base up to July of 2012. A manual search for conference
proceedings relevant to this topic, references from rele-
vant reports of clinical trials and review articles was
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and unreported material. The following search strategy,
using the grouped terms, was used for MEDLINE, and
was modified to suit other databases.













13. 7 and 12
Study selection and data extraction
Two investigators (XCL, GY) independently reviewed the
titles and abstracts to select potential references according
to the criteria that established above. All full articles with
potentially relevant trials were retrieved. Then, they read
the selected articles independently and made a final deci-
sion for selection or not. Discrepancies were discussed
and resolved by agreement or consultation with a third au-
thor (ZGQ).
A standardized data extraction form was used to extract
data, including patients, methods, interventions and out-
comes. The reasons for the exclusion of studies were
recorded accordingly. For eligible studies, two review
authors (XCL, GY) extracted the data independently. Dis-
agreements were resolved through consultation with a
third party (ZGQ).
Risk of bias in individual studies
The methodological quality of RCTs was assessed inde-
pendently using the Cochrane Handbook for Systematic
Reviews of Interventions [updated September 2009]. Two
investigators (XCL, GY) independently evaluated the
methodological quality of the included articles. Disagree-
ments were resolved through consensus or discussed
with a third author (ZGQ).
Results
Description of studies
We identified 501 potentially relevant articles. After re-
moval of duplicates, 124 records remained. After going
through the titles and abstracts, we excluded 69 papers
with at least one of following reasons: (1) not clinical trials;
(2) case report or lack of control group, and (3) efficacy of
SZRD not being objective of study. By reading the full textof the remaining 55 articles, 10 were excluded because
control group is CHM treatment rather than WCM; 25
were excluded for not RCT or not real RCT; 4 papers were
excluded as a result of not carried out random method; 2
papers were removed due to deficiency of useful data; 2 for
the treatment courses being either not mentioned or less
than 2 weeks. Ultimately, 12 eligible studies were selected
in present study [31-42]. The screening process is summar-
ized in a PRISMA 2009 flow diagram (Figure 1).Characteristics of included studies
The basic characteristics of the 12 trials are summarized
in Table 1. A total of 1376 adult insomniac participants
were included in these 12 trials. The disease duration ran-
ged from 1 months [33] to 16 years [34]. 8 were diagnosed
according to CCMD [32-39], 3 based on GCTNPCM cri-
teria [31,40,41], remaining 1 were diagnosed according to
both CCMD and GCTNPCM criteria [42]. All trials
adopted SZRD monotherapy or adjunct therapy in the
treatment group for insomnia. One study was three-group
design study [42], in which both SZRD monotherapy and
SZRD adjunct therapy were compared with the WCM
control. Thus, 9 were monotherapy and the rest of 4 stud-
ies were combined with the WCM to treat the insomnia.
All the patients in the control groups were received
Benzodiazepine treatment, 4 used diazepam [33,34,37,41],
4 used estazolam [32,36,39,40], 2 used alprazolam [31,42],
lorazepam [32] and oxzaepam [35] just have 1 study, re-
spectively. The duration of treatment was varied from
14 days [31,33,39,42] to 30 days [35]. Clinical efficacy was
observed in 11 studies, but the standard is different, in
which 8 adopted TCM standard; 2 studies [35,42] used the
reducing score rate of PSQI; 1 trial [36] applied home-
made criteria. PSQI score was tested in 2 studies [37,42].
Adverse effects were reported in 3 studies [31,36,42], while
no mention in the other studies (Table 1).Risk of bias in included studies
We utilized the criteria recommended by Cochrane
Handbook for Systematic Reviews to assess the risk of bias
in the 12 articles included. The number of criteria met
varied from 1/8 to 3/8, all of the methodological quality
are no more than 3/8 score. Although all included studies
claimed randomization, only 3 articles reported the
method of random sequences generation [32,37,38]. No
trial described allocation concealment. Only one study
reported the blinding of participants [42]. Only one trial
described intention-to-treat analyses (ITT) [36]. Non-
selective reporting was found in 3 trials [31,36,41]. Five
studies existed certain degree other potential threats to
validity. Therefore, all of the included trials were deemed
to have an unclear risk of bias. The methodological quality
of each study was summarized in Table 2.
PRISMA 2009 Flow Diagram
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Figure 1 PRISMA 2009 Flow Diagram.
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SZRD versus placebo
No study was conducted to evaluate SZRD versus pla-
cebo control that met the included criteria. However, a
self-controlled design study was 60 insomniac patients
receiving placebo for one week, subsequently receiving
capsules containing 1 gm of SZRD 30 min before bed-
time each night for two weeks, and followed by another
week of placebo administration. The results indicated
that all ratings of sleep quality and well-being (sleep la-
tency, sleep time, number of intermittent awakenings,
how well slept and how felt on awakening based on
seven-point scale) during active treatment were statisti-
cally significant improvements (P < 0.001) when com-
pared with both placebo periods, and that no side effects
were noted [43].
SZRD versus western medication
There were 9 RCTs comparing SZRD monotherapy with
conventional medicine (Table 1). The clinical effectiverates were assessed in all 8 included studies [31,33,36-
39,41,42]. Benzodiazepines was the only Western medi-
cation comparator. The clinical effective rates in the
SZRD groups varied from 90% to 96.7%, with a mean of
92.5%, while the clinical effective rates in the benzodi-
azepine groups ranged from 66.7% to 93%, with a mean
of 78.9%. However, meta-analysis could not be per-
formed owing to the high clinical heterogeneity and low
methodological quality of the included studies. Although
the all 8 included studies used the clinical effective rate
as an outcome measure, trials numbers are too small to
draw a meaningful funnel plot [44]. Therefore, we also
did not conduct the funnel plot analysis.
Based on the sleep questionnaires, one RCT reported
significant effects of SZRD therapy for improving PSQI
score when compared with 5 mg diazepam (p < 0.05) [37];
one RCT reported for improving score of Spiegel sleep
questionnaires (P < 0.05) when compared with estazolam
(p < 0.05) [39]. Interestingly, Yuan et al. [38] reported that
90 days follow up was done to gather the information of
Table 1 Basic characteristics of the included studies
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Table 1 Basic characteristics of the included studies (Continued)
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this study, and the results indicated that time to onset in
SZRD group was significantly slower than in estazolam
group; considerable theraputic effect was found in both
groups at the seven days; the efficacy in SZRD group was
better than that in estazolam group at the 14 days; in with-
drawal period (16 days to 90 days), symptoms of estazo-
lam group rebound quickly and markdly, while sleep
rebound slowly in SZRD group and less that that in esta-
zolam group. However, with the extensions of the follow
up time, lost cases increased significantly.
SZRD plus conventional medicine versus conventional
medicine alone
There are 4 RCTs comparing SZRD plus Western drug
therapy with Western drug therapy alone [32,35,40,42]
(Table 1). According to the reducing score rate of PSQI,
Wu et al. [42] indicated that there was significant differ-
ence of the reducing score rate of PSQI when compared
the SZRD plus alprazolam groups with alprazolam alone
groups (P<0.05). However, Tan [35] indicated that insom-
niac patients receiving SZRD plus Oxazepam therapy have
not significantly affected the reducing score rate of PSQI
when compared with Oxazepam alone (p > 0.05). Based
on the clinical effective rate, Wu et al. [42] and Zou et al.
[40] reported the effect of SZRD plus alprazolam or plus
estazolam for improving clinical effective rate compared
with alprazolam alone or estazolam alone, respectively
(P < 0.05). Yu et al. [32] tested the effects of SZRD plus
lorazepam compare with lorazepam alone in insomniac
patients. SZRD was shown to significantly improve the
score of sleep dysfunction rating scale and hamilton
anxiety scale (HAMA) than that of lorazepam alone
(P < 0.05). However, there was no significant difference in
Clinical general impression scale (CGI).
Adverse events
Adverse event monitoring was only reported in 3 studies
[36,42], but no mention of side effects in the other 9 trials.
No serious adverse effects were noted in these studies. Yu
et al. [36] reported that adverse event occurred 2 cases in
the SZRD group and 15 cases in the estazolam group
(P < 0.01). In the study by Wu et al. [42], no adverse event
was happened in the SZRD group, there were 47cases
(18.1%) in the SZRD plus alprazolam group,whereas the
alprazolam group occurred 34 cases (48.57%) (p < 0.01).
Wu et al. [31] reported that no obvious adverse event was
happened in the SZRD group, whereas there were 34 cases
(48.6%) in the alprazolam group (p < 0.01).
Discussion
Summary of evidence
This study is the update systematic review of English
and Chinese literature to determine the efficacy andsafety of SZRD for insomnia. The 12 claimed RCTs with
the total of 1376 insomniac patients that met the inclu-
sion criteria. Despite the apparent reported positive find-
ings, it is premature to conclude the efficacy of SZRD
for the treatment of insomnia because the included stud-
ies were of generally poor quality and had small sample
sizes. This systematic review suggests that SZRD may be
safe for managing insomnia. However, only three studies
reported adverse events; it is difficult to draw a definite
conclusion.Limitations
The methodological quality of the included RCTs was gen-
erally poor. There are a number of methodological weak-
nesses in the primary studies. Randomization is necessary
to avoid selection bias. However, only 3 articles reported
the method of random sequences generation [32,37,38]. In
addition, none of the included trials described allocation
concealment. It has been shown that trials with inadequate
concealment of allocation or unclear reporting of the tech-
nique used were on average 18% more “beneficial” than
effect estimates from trials with adequate concealment
(95% CI 5% to 29%) [45]. Our decision to exclude quasi-
randomisation trials might need a comment. Jadad et al.
[46] demonstrated that methods of allocation using date
of birth, date of admission, hospital numbers, or alterna-
tion should be not regarded as appropriate. Moreover,
Schulz et al. [47] found that odds reductions were exag-
gerated by up to 30% for trials that did not have clear con-
cealment, and by 41% for inadequately concealed trials.
We thus included the unclear randomised trial, but
excluded quasi-randomised trial. We hope that “unclear”
random is less risk of selection bias than that of definitely
“inadequate” random.
Blinding is an essential method for preventing research
outcomes from being influenced by either the placebo ef-
fect or the observer bias. However, only 1 study reported
the blinding of participants [42]. Moreover, an appropriate
placebo control is critical for any study exploring insom-
nia, mood or anxiety outcomes, as placebo-response is no-
toriously high in this area of study [48]. However, no
placebo control was used to mask participants and care
providers. Without a rigorous control for placebo effect,
the results of these studies would be positive because of
nonspecific placebo effects [49]. One of the main reasons
for not using placebos in these trials may be the difficulties
involved in preparing a liquid form (decoction) to have
the same color, taste and flavor as a comparator, and thus
the formulations are advised to be prepared in the form of
capsule or pill [48,50,51].
ITT analysis has been considered as an important strat-
egy in pragmatic randomised controlled trials for assuring
two main purposes: (1) maintains treatment groups that
Table 2 The methodological quality of included studies
based on the Cochrane handbook
A B C D E F G H
WU2005 [31] ? - - - - + + -
Yu 2005 [32] + - - - - + ? +
Tan 2006 [35] ? - - - - + - -
Yu 2006 [36] ? - - - - - + -
Wu 2008 [42] ? - + - - + ? -
She2009 [37] + - - - - + ? +
Yuan2009 [38] + - - - - + ? +
Luo 2009 [34] ? - - - - + ? -
Zou 2011 [40] ? - - - - + - -
Cong 2011 [41] ? - - - - + + -
Feng 2011 [39] ? - - - - + ? -
Liu 2012 [33] ? - - - - + - -
A: Adequate sequence generation; B: Concealment of allocation; C: Blinding
(patient); D: Blinding(investigator); E: Blinding(assessor); F: Incomplete outcome
data addressed (ITT analysis); G:Free of selective reporting; H: other potential
thereat to validity. +: Yes, -: No, ?: Unclear.
Xie et al. BMC Complementary and Alternative Medicine 2013, 13:18 Page 9 of 12
http://www.biomedcentral.com/1472-6882/13/18are similar; and (2) it allows for non-compliance and
deviations from policy by clinicians [52]. However, only 1
trial [36] stated whether they analyzed the data based on
the ITT principle. In addition, information on dropout
rates and withdrawal was not provided. In the absence of
withdrawal reporting, information on handling of possible
dropout data and the impact of dropouts on the reliability
of trials is rendered suspect. Only 1 trial described the
duration of follow-up clearly [38]. Lack of follow-ups led
to difficulty in accounting for the long-term efficacy of
SZRD treatment for insomnia.
Selective publishing and reporting are other major
causes for bias, that must be considered. Non-selective
reporting was found only in 3 trials [31,36,41]. It is con-
ceivable that several negative RCTs remained unpub-
lished and thus distorted the overall picture [53-56]. In
the present study, most of the included trials reported
positive results and all included trials come from China.
However, some countries, including China, published
unusually high proportions of positive results, and found
publication bias as a possible explanation [57]. Similarly,
we could not exclude the possibility of publication bias
because most of the trials claimed that the tested treat-
ments were effective, though we did not conduct the
funnel plot analysis due to the small number of trials. In
September 2004, the members of the International
Committee of Medical Journal Editors (ICMJE) pub-
lished a statement requiring that all clinical trials must
be registered in order to be considered for publication
[58]. However, none of included studies in this review
had been formally registered. Thus, protocols were not
available to confirm free of selective reporting.The clinical heterogeneity would be very significant due
to the variations in study quality, participants, intervention,
control, and outcome measures. Thus, it was not possible
to perform a pooling analysis of the trials.
A correct diagnosis is a crucial issue in every field lack-
ing objective/instrumental markers of the disorder/syn-
drome under investigation [59]. All included studies
applied national-specific diagnostic criteria (CCMD or
GCTNPCM) for enrollment. CCMD-3 was the well
defined diagnostic criteria for a precise clinical diagnosis
of insomnia developed by the Chinese Society of Psych-
iatry (CSP). Moreover, GCTNPCM diagnostic criteria is
not a TCM diagnosis pattern which examining the tongue,
pulse, and eliciting constipation symptoms associated with
TCM syndromes, but a modern criteria for insomnia of
New Patent Chinese Medicines. Hence, both two diagnos-
tic criteria specified primary insomnia and excluded
comorbid insomnia. Although there is no gold standard
for diagnosing insomnia, adopting some popular inter-
national diagnostic criteria such as Diagnostic and Statis-
tical Manual of Mental Disorders (DSM-IV) and
International Classification of Diseases (ICD-10) is worth
promoting.
The quality control of herbal preparations is crucial for
the validity of the study results. However, no trials men-
tioned in this important issue. To assess the efficacy of
SZRD in a clinical study, all subjects should be given
exactly the same intervention in terms of product identity,
purity, dosage, and formulation. It is worthwhile to also
point out that various benzodiazepines were used in these
studies. Although belonging to the same drug class, indi-
vidual benzodiazepine shows different efficacies in the
treatment of insomnia [60]. Hence, a general conclusion
stating the superiority of SZRD over benzodiazepines irre-
spective of their differences in half life, potency, dosage
and adverse effect might be an inaccurate statement.
There are many outcome measures available to evalu-
ate the effectiveness of insomnia treatments [61], and a
number of outcome measures used in the studies. Unless
the used outcome measures have established reliability
and validity, data derived from them are subject to bias.
However, the common use of “clinical efficacy rate” as
an ancillary outcome measure through subjective quali-
tative scores such as “clinical cure”, “markedly effective”,
“effective”, and “ineffective” in Chinese are not inter-
nationally recognized, and the validity and reliability of
that was uncertain in assessing the outcome. Future
trials to comply with international standards in the
evaluation of treatment effect can solve this problem.
Moreover, the time of the measurement was different
among the trials, which leads to difficulties in interpret-
ing the effects.
One of the hallmarks of a good quality trial is that it
should have an adequate sample size with sufficient
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treatment groups. However, there are small sample size
in most of included studies. Trials with inadequate
sample sizes often run the risk of overestimating inter-
vention benefits [62]. In addition, no trials conducted
pre-trial estimation of sample size, which indicated the
lack of statistical power to ensure appropriate estimation
of the therapeutic effect [63]. The results were likely to
be underpowered [64].
No study outside of China is another weakness that
potentially limited the generalizability of the findings. In
addition, the use of composite outcome measures such
as clinical cure, markedly effective, effective and ineffect-
ive to evaluate overall improvement of symptoms also
limits the generalization of the findings.
The SZRD evaluated in this review generally appeared
to be safe and well tolerated by insomniac patients.
Interestingly, SZRD can possibly reduce the adverse-
effect of alprazolam [42]. However, the safety of their
use for SZRD could not be confirmed because only 2
studies mentioned the safety of interventions or investi-
gated adverse events as one of the secondary outcome
measures. Investigators of these studies might have
underestimated possible adverse events.Implications for practice
Due to the poor methodological quality and high clinical
heterogeneity of the included studies, and the small
number of trials included in this systematic review, the
current evidence is insufficient to support the efficacy of
SZRD for insomnia. SZRD appeared to be well tolerated,
but no confirmed conclusion can be reached because
lack of RCTs assessed the safety. Therefore, current evi-
dence from present systematic review is insufficient to
recommend the routine use of SZRD for insomnia.
However, It should be remembered that a lack of scien-
tific evidence does not necessarily mean that the treat-
ment is ineffective [65].Implications for research
The only extensively researched herbal medicine for in-
somnia to date is valerian (either as a monotherapy or in
combination with kava or hops), but weak evidence for
the use of herbal medicines including valerian and Kava,
suggesting that further research on other herbal medi-
cines with potential hypnotic effects is encouraged as
current research in these areas is in their infancy [66].
SZRD is a well-known herb prescription for the treatment
of insomnia. Although the present evidence is insufficient
for support efficacy of SZRD, it is a promising candidate
for further insomniac clinical trials. In addition, sufficient
information about species, geographical origin of herbs,seasons of collecting and quality of the preparations
should be provided [67].
Owing to a major concern in methodological quality,
we recommend that the CONSORT 2010 statement
[68,69], which consists of a 25-item checklist to deter-
mine study quality and rigor, should be used as a guide-
line when designing and reporting RCTs in the future.
All clinical trials must be registered before the enroll-
ment of the first patient, according to ICMJE statement
[58]. Details of randomization and allocation conceal-
ment should be sufficiently described. The use of appro-
priate blinding procedures should be promoted. The
development of appropriate sham or placebo controls
and protocol for blinding should be considered with
assessing and reporting of the success of the blinding
procedures. ITT analysis is also recommended, in case
of dropout and/or withdrawal. In particular, trials
should have sufficiently large samples, ideally based on
formal power calculations, and include appropriately
long treatment periods and treatment frequencies.
Widely recognized diagnostic criteria and validated pri-
mary outcome measures should be consolidated and
used consistently. Attention should also be paid to the
incidence of adverse events. Appropriate statistical ana-
lyses should be carried out for the baseline data and
outcome results. Since insomnia may wax and wane
with or without treatment, a longer followup period
with serial measurements of outcomes is important to
determine the genuine effectiveness and longterm effect
of SZRD.
Conclusions
There is insufficient evidence regarding the efficacy of
SZRD for the treatment of insomnia because of the
small number of trials and the small total sample sizes
of the included trials. Another main reason to under-
mine the validity of findings is high clinical heterogen-
eity and low methodological quality of the included
trials. Owing to the lack of adequate safety data, there is
insufficient evidence to conclude the safety of SZRD for
insomnia. Further large sample-size and rigorously
designed RCTs are needed.
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